リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3-4N0M0 (UICC 8th edition): outcomes and patterns of failure」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3-4N0M0 (UICC 8th edition): outcomes and patterns of failure

成田 篤哉 横浜市立大学

2020.03.25

概要

The evidence for stereotactic body radiotherapy (SBRT) is meagre for patients with clinical T3-4N0M0 non- small cell lung cancer (8th Edition of the Union for International Cancer Control (UICC)). This study retro- spectively investigated clinical outcomes following SBRT for such patients. Among consecutive patients treated with SBRT, patients staged as cT3-4N0M0 by all criteria were examined, most of whom were unsuitable to che- moradiotherapy due to their fragile characters. Clinical outcomes were evaluated and factors associated with out- comes were investigated. Between 2005 and 2017, 70 eligible patients (T3: 58, T4: 12; median age 81 (63–93) years) were identified. Median follow-up duration was 28.6 (1.0–142.5) months. No adjuvant chemotherapy was administered. The 3-year local recurrence rates were 15.8% and 16.7% in T3 and T4 patients, respectively, and they were significantly lower in the high-dose group (3.1% vs 28.6%, P < 0.01). Multivariate analyses showed that the dose-volumetric factor was the significant factor for local recurrence. The 3-year regional and distant metastasis rates, cancer-specific mortality, and overall survival in T3 and T4 patients were 22.7% and 25.0%, 26.5% and 33.3%, 32.2% and 41.7%, and 39.5% and 41.7%, respectively. Only age was correlated with overall survival. Radiation pneumonitis ≥grade 3 and fatal hemoptysis occurred in 3 and 1 patients, respectively. SBRT for cT3-4N0M0 lung cancer patients achieved good local control. Survival was rather good considering that patients were usually frail, staged with clinical staging, and were not given adjuvant chemotherapy, and it may be comparable to surgery. To validate these outcomes following SBRT, a prospective study is warranted.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Siegel R-L, Miller K-D, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7–30.

2. Rami-Porta R, Bolejack V, Crowley J et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015;10: 990–1003.

3. Rami-Porta R, Bolejack V, Giroux D-J et al. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2014;9:1618–1624.

4. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (2017/12/26 2017, date last accessed).

5. Schneider B-J, Daly M-E, Kennedy E-B et al. Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol 2018;36:710–719.

6. Guckenberger, M, Andratschke N, Dieckmann K et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 2017;124: 11–17.

7. Videtic G-M-M, Donington J, Giuliani M et al. Stereotactic body radiation therapy for early-stage non-small cell lung can- cer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 2017;7:295–301.

8. Postmus P-E, Kerr K-M, Oudkerk M et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv1–iv21.

9. Eriguchi T, Takeda A, Sanuki N, et al. Stereotactic body radio- therapy for T3 and T4N0M0 non-small cell lung cancer. J Radiat Res 2016;57:265–272.

10. Takeda A, Kunieda E, Sanuki N, et al. Dose distribution analysis in stereotactic body radiotherapy using dynamic conformal mul- tiple arc therapy. Int J Radiat Oncol Biol Phys 2009;74:363–369.

11. Kanda Y. Investigation of the freely available easy-to-use soft- ware ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48:452–458.

12. Stahl J-M, Corso C-D, Verma V et al. Trends in stereotactic body radiation therapy for stage I small cell lung cancer. Lung Cancer 2017;103:11–16.

13. Dalwadi S-M, Szeja S-S, Bernicker E-H et al. Practice patterns and outcomes in elderly stage I non-small-cell lung cancer: A 2004 to 2012 SEER Analysis. Clin Lung Cancer 2018;19:e269–e76.

14. Howington J-A, Blum M-G, Chang A-C et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and man- agement of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e278S–e313S.

15. Kawaguchi K, Miyaoka E, Asamura H et al. Modern surgical results of lung cancer involving neighboring structures: a retro- spective analysis of 531 pT3 cases in a Japanese Lung Cancer Registry Study. J Thorac Cardiovasc Surg 2012;144:431–437.

16. Watanabe S, Asamura H, Miyaoka E et al. Results of T4 surgical cases in the Japanese Lung Cancer Registry Study: should medi- astinal fat tissue invasion really be included in the T4 category? J Thorac Oncol 2013;8:759–765.

17. Suemitsu R, Ueda H, Shikada Y et al. Relationship of tumor size to survival in patients with pT2N0 lung cancer. Asian Cardiovasc Thorac Ann 2006;14:30–34.

18. Lee C-Y, Byun C-S, Lee J-G et al. The prognostic factors of resected non-small cell lung cancer with chest wall invasion. World J Surg Oncol 2012;10:9.

19. Matsuoka H, Nishio W, Okada M et al. Resection of chest wall invasion in patients with non-small cell lung cancer. Eur J Cardiothorac Surg 2004;26:1200–1204.

20. Ahmad U, Crabtree T-D, Patel A-P et al. Adjuvant chemotherapy is associated with improved survival in locally invasive node negative non-small cell lung cancer. Ann Thorac Surg 2017;104:303–307.

21. Moreno A-C, Morgensztern D, Yu J-B et al. Impact of preopera- tive radiation on survival of patients with T3N0>7-cm non-small cell lung cancers treated with anatomic resection using the Surveillance, Epidemiology, and End Results database. J Surg Res 2013;184:10–18.

22. Choi Y, Lee I-J, Lee C-Y et al. Multi-institutional analysis of T3 subtypes and adjuvant radiotherapy effects in resected T3N0 non- small cell lung cancer patients. Radiat Oncol J 2015;33:75–82.

23. Wisnivesky J-P, Henschke C, McGinn T et al. Prognosis of Stage II non-small cell lung cancer according to tumor and nodal status at diagnosis. Lung Cancer 2005;49:181–186.

24. Strauss G-M, Herndon J-E 2nd, Maddaus M-A et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043–5051.

25. Morgensztern D, Du L, Waqar S-N et al. Adjuvant chemother- apy for patients with T2N0M0 NSCLC. J Thorac Oncol 2016; 11:1729–1735.

26. Dunlap N-E, Larner J-M, Read P-W et al. Size matters: a com- parison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg 2010;140:583–589.

27. Koshy M, Malik R, Weichselbaum R-R et al. Increasing radi- ation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2015; 91:344–350.

28. Shaverdian N, Tenn S, Veruttipong D et al. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy. Br J Radiol 2016;89: 20150963.

29. Guckenberger M, Klement R-J, Allgauer M et al. Applicability of the linear-quadratic formalism for modeling local tumor con- trol probability in high dose per fraction stereotactic body radio- therapy for early stage non-small cell lung cancer. Radiother Oncol 2013;109:13–20.

30. Kestin L, Grills I, Guckenberger M et al. Dose-response rela- tionship with clinical outcome for lung stereotactic body radio- therapy (SBRT) delivered via online image guidance. Radiother Oncol 2014;110:499–504.

31. Oku Y, Takeda A, Kunieda E, et al. Analysis of suitable pre- scribed isodose line fitting to planning target volume in stereotactic body radiotherapy using dynamic conformal mul- tiple arc therapy. Pract Radiat Oncol 2012;2:46–53.

32. Dickey M, Roa W, Drodge S et al. A planning comparison of 3- dimensional conformal multiple static field, conformal arc, and volumetric modulated arc therapy for the delivery of stereotactic body radiotherapy for early stage lung cancer. Med Dosim 2015; 40:347–351.

33. Atagi S, Kawahara M, Yokoyama A et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012;13:671–678.

34. Verma V, McMillan M-T, Grover S et al. Stereotactic body radi- ation therapy and the influence of chemotherapy on overall sur- vival for large (≥5 centimeter) non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2017;97:146–154.

35. Louie A-V, van Werkhoven E, Chen H et al. Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial. Radiother Oncol 2015; 117:44–48.

36. Shaverdian N, Wang P-C, Steinberg M et al. The patient’s per- spective on stereotactic body radiation therapy (SBRT) vs. sur- gery for treatment of early stage non-small cell lung cancer (NSCLC). Lung Cancer 2015;90:230–233.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る